Erratum: Role of Tumor Pericytes in the Recruitment of Myeloid- Derived Suppressor Cells (Journal of the National Cancer Institute (2015) 107:10 (djv209) DOI: 10.1093/jnci/djv209);Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells

Journal of the National Cancer Institute

Volumn 107, Issue 10, 2015, Pages

  Hong, Jong Wook ^a   Tobin, Nicholas P ^b   Rundqvist, Helene ^a   Li, Tian ^a   Lavergne, Marion ^a   García Ibáñez, Yaiza ^a   Qin, Hanyu ^a,d   Paulsson, Janna ^b   Zeitelhofer, Manuel ^a   Adzemovic, Milena Z ^a   Nilsson, Ingrid ^a   Roswall, Pernilla ^a   Hartman, Johan ^b   Johnson, Randall S ^a,c   Östman, Arne ^b   Bergh, Jonas ^b   Poljakovic, Mirjana ^a,b   Genové, Guillem ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CALGRANULIN B; CD33 ANTIGEN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; PROGESTERONE RECEPTOR; SHORT HAIRPIN RNA; VASCULOTROPIN A; CD11B ANTIGEN; CHEMOKINE RECEPTOR; GR-1 PROTEIN, MOUSE; MEMBRANE ANTIGEN; TRANSCRIPTOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE SILENCING; HAZARD RATIO; HUMAN; INCUBATION TIME; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; BREAST TUMOR; CELL HYPOXIA; CELL MOTION; FLOW CYTOMETRY; GENETICS; METABOLISM; PATHOLOGY; SUBCUTANEOUS TISSUE; SWEDEN;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, SURFACE; BREAST NEOPLASMS; CELL HYPOXIA; CELL MOVEMENT; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMANS; INTERLEUKIN-6; MICE; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; PERICYTES; RECEPTORS, CHEMOKINE; SUBCUTANEOUS TISSUE; SWEDEN; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84944684604     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv434     Document Type: Erratum

References (41)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674.
2. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316(8):1324-1331.
3. Grivennikov SIS, Greten FRF, Karin MM. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
4. Proebstl D, Voisin M-B, Woodfin A, et al. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J Exp Med. 2012;209(6):1219-1234.
5. Nisancioglu MH, Mahoney WM, Kimmel DD, Schwartz SM, Betsholtz C, Genove G. Generation and characterization of rgs5 mutant mice. Mol Cell Biol. 2008;28(7):2324-2331.
6. Hamzah J, Jugold M, Kiessling F, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410-414.
7. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215.
8. Olson LE, Soriano P. PDGFR? signaling regulates mural cell plasticity and inhibits fat development. Dev Cell. 2011;20(6):815-826.
9. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-145.
10. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
11. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
12. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67(20):10019-10026.
13. Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60(9):1269-1279.
14. Chen M-F, Kuan F-C, Yen T-C, et al. IL-6-stimulated CD11b + CD14 + HLADR myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget. 2014;5(18):8716-8728.
15. Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011;108(41):17111-17116.
16. Nisancioglu MH, Betsholtz C, Genove G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010;70(12):5109-5115.
17. Lindblom P, Gerhardt H, Liebner S, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17(15):1835-1840.
18. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1(10):1029-1034.
19. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550-13555.
20. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
21. Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557-561.
22. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003;112(8):1142-1151.
23. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666-4675.
24. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839-5849.
25. Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or melan-A-specific T cells. Clin Cancer Res. 2014;20(6):1601-1609.
26. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499-4506.
27. Furuhashi M, Sjoblom T, Abramsson A, et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 2004;64(8):2725-2733.
28. Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxiaassociated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21(1):66-81.
29. Ortiz ML, Kumar V, Martner A, et al. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J Exp Med. 2015;212(3):351-367.
30. Kitano S, Postow MA, Ziegler CGK, et al. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res. 2014;2(8):812-821.
31. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 Cells in Cancer: The Ultimate Identity Crisis. Front Immunol. 2014;5.
32. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233-4244.
33. Yonenaga Y, Mori A, Onodera H, et al. Absence of smooth muscle actinpositive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology. 2005;69(2):159-166.
34. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116(3):642-651.
35. Condamine T, Ramachandran I, Youn J-I, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015;66(1):97-110.
36. Raines SM, Richards OC, Schneider LR, et al. Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity. Am J Physiol Endocrinol Metab. 2011;301(3):E517-E526.
37. Zymek P, Bujak M, Chatila K, et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol. 2006;48(11):2315-2323.
38. Kang EJ, Major S, Jorks D, et al. Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions. Neurobiol Dis. 2013;52:204-218.
39. Genove G, Mollick T, Johansson K. Photoreceptor degeneration, structural remodeling and glial activation: A morphological study on a genetic mouse model for pericyte deficiency. Neuroscience. 2014;279:269-284.
40. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160(3):985-1000.
41. O'Keeffe MB, Devlin AH, Burns AJ, et al. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol Res. 2008;17(3):93-101.